Skip to content

Released May 11, 2023, before the open

10-Q filed May 11, 2023, 41 days after period end · 0001628280-23-017423

Q1 2023 · 10-Q
Revenue$0.00no prior Q1 2022 on fileno prior Q4 2022 on file
Net Income-$39.40MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.44N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$40,033,000N/M
Operating Cash Flow-$41,561,000N/M
Free Cash Flowderived-$43,560,000N/M

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021
Revenue$0.00——
Net Income-$39.40M-$23.84M-$86.66M
EPS Diluted-$0.44-$1.58—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR